<pages><page bbox="0.000,0.000,720.000,540.000" id="1" rotate="0">
<title archetypal_index="0" bbox="55.152,297.678,628.458,433.668" id="0" size="39.96" Annotation_index="0">Special cardiac safety concerns: 
QT prolongation and  
Valvulopathy <textline bbox="55.152,393.708,628.458,433.668" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 0.906, 0.00392)" size="39.960">Special cardiac safety concerns: </textline>
<textline bbox="160.030,345.678,535.214,385.638" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 0.906, 0.00392)" size="39.960">QT prolongation and  </textline>
<textline bbox="229.060,297.678,454.834,337.638" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 0.906, 0.00392)" size="39.960">Valvulopathy </textline>
</title>
<normal_text archetypal_index="1" bbox="143.950,204.770,516.670,228.770" id="1" size="24.0" Annotation_index="1">Shari L. Targum, MD, FACC, FACP <textline bbox="143.950,204.770,516.670,228.770" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 1, 0.6)" size="24.000">Shari L. Targum, MD, FACC, FACP </textline>
</normal_text>
<normal_text archetypal_index="2" bbox="245.500,173.090,474.532,197.090" id="2" size="24.0" Annotation_index="2">Medical Team Leader <textline bbox="245.500,173.090,474.532,197.090" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 1, 0.6)" size="24.000">Medical Team Leader </textline>
</normal_text>
<normal_text archetypal_index="3" bbox="168.790,125.077,592.696,166.722" id="3" size="20.052" Annotation_index="3">Division of Cardiovascular and Renal Products,  
CDER, FDA <textline bbox="168.790,146.682,592.696,166.722" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 1, 0.6)" size="20.040">Division of Cardiovascular and Renal Products,  </textline>
<textline bbox="324.000,125.077,432.025,145.141" colourspace="DeviceGray" font="ArialMT" ncolour="(1, 1, 0.6)" size="20.064">CDER, FDA </textline>
</normal_text>
</page>
</pages>